Please login to the form below

Not currently logged in
Email:
Password:

Martin Shkreli

This page shows the latest Martin Shkreli news and features for those working in and with pharma, biotech and healthcare.

Fireworks likely at Senate drug pricing hearing today

Fireworks likely at Senate drug pricing hearing today

as Martin Shkreli’s former company Turing Pharma racking up the price of an old antibiotic and Mylan with its steep price increases for EpiPen, a life-saving treatment for severe

Latest news

  • Profit: the ugly, dirty truth? Profit: the ugly, dirty truth?

    One of the most infamous quotes (of many) from a certain Martin Shkreli, the so-called ‘Pharma Bro’, currently serving seven years for fraud in the federal prison in Fort Dix,

  • Theranos and its CEO settle 'massive fraud' charges Theranos and its CEO settle 'massive fraud' charges

    A separate case will proceed again Balwani. Holmes will, however, avoid jail time, unlike former Turing CEO Martin Shkreli, who was arrested in 2015 by the FBI on securities fraud charges

  • Connecting the dots Connecting the dots

    In a world like this, how many Marathons, Valeants and Martin Shkreli’s do you think there would be?

  • Making a list and checking it twice… Making a list and checking it twice…

    Let's start with an obvious one: prices and price increases. The hangover effect of Martin Shkreli and Valeant Pharmaceuticals in 2015 continued to haunt the industry along with new dramas

  • EpiDemic EpiDemic

    And the next egregious drug-pricing headline is yet to come. But like Valeant and Martin Shkreli before it, the EpiPen narrative teaches us some important lessons.

More from news
Approximately 5 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Trust me, I’m from pharma Trust me, I’m from pharma

    However, controversies around drug pricing – fuelled by the unhelpful interventions of Martin Shkreli as the pin-up boy for big, bad pharma – have undermined progress and reinforced the view that the

  • Pharma deals in September 2015 Pharma deals in September 2015

    treat toxoplasmosis, being given a 5, 000% price increase ($13.50 per pill to $750), to “fund future research into the disease” and the subsequent backlash against its CEO Martin Shkreli ... in net cash to fund its near-term development needs and

  • Pharma deals during February 2014 Pharma deals during February 2014

    According to Martin Shkreli, founder and CEO: “We also intend to move quickly to pursue FDA approval of Chenodal for CTX.".

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics